Modifiedharvard pilgrim health carePolicy N/A

Actemra (tocilizumab) subcutaneous — Prior Authorization Coverage Criteria

Customize your policy alerts

Sign up for all harvard pilgrim health care policy alerts

Know when harvard pilgrim health care releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Prior authorization criteria for coverage of Actemra (tocilizumab) subcutaneous across Harvard Pilgrim and Tufts commercial products; includes initial and reauthorization requirements, program-level limits, and formulary preference updates.

Policy Summary

Payerharvard pilgrim health care

PolicyActemra (tocilizumab) subcutaneous — Prior Authorization Coverage Criteria

Policy CodePolicy N/A

Change TypeMaterial coverage and operational updates (approval limits, reauthorization, preferred product change)

Effective DateMar 1, 2026

Last ReviewOct 14, 2025

Next Review DateN/A

Key ActionObtain prior authorization and document diagnosis, prior medication trials, prescriber specialty, and absence of concurrent targeted therapy; approvals are limited to 12 months and require annual reauthorization.

SourceLink

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Modifiedharvard pilgrim health carePolicy N/A

Actemra (tocilizumab) subcutaneous — Prior Authorization Coverage Criteria

Customize your policy alerts

Sign up for all harvard pilgrim health care policy alerts

Know when harvard pilgrim health care releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payerharvard pilgrim health care

PolicyActemra (tocilizumab) subcutaneous — Prior Authorization Coverage Criteria

Policy CodePolicy N/A

Change TypeMaterial coverage and operational updates (approval limits, reauthorization, preferred product change)

Effective DateMar 1, 2026

Last ReviewOct 14, 2025

Next Review DateN/A

SourceLink

POLICY UPDATE CHANGES

Approvals limited to 12 months with annual reauthorization coverage criteria added.

Provider requirements no longer allow 'with in consultation with the specialist'.

Added coverage criteria to prevent duplicative targeted immunomodulator therapy and updated diagnosis and initial authorization prerequisite language.

Replaced Humira with Simlandi as the preferred adalimumab product.

Updated biologic prerequisites for pJIA to include Rinvoq, Xeljanz, and later Cimzia as applicable agents.

Limitations language stating needle phobia qualifies as a contraindication was removed.

annualreauthorization frequency required

12 mostandard approval duration for biologic approvals

>=18; >=2age thresholds

Simlandipreferred adalimumab change

3pJIA biologic updates

Nonecodes listed

Coverage Criteria for Actemra (tocilizumab) subcutaneous

Initial Authorization — Giant Cell Arteritis

Covered when ALL of the following are met for giant cell arteritis (initial):

GCA Initial Criteria: 1. Documented diagnosis of giant cell arteritis; 2. Patient is at least 18 years of age or older; 3. Prescribed by a rheumatologist or neurologist; 4. Documentation of history of failure to a systemic corticosteroid, unless contraindicated (document drug, date and duration of trial); 5. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

Initial Authorization — Juvenile Idiopathic Arthritis

Covered when ALL of the following are met for juvenile idiopathic arthritis (initial):

JIA Initial Criteria: 1. Documented diagnosis of active polyarticular or systemic juvenile idiopathic arthritis; 2. Patient is at least 2 years of age or older; 3. Prescribed by a rheumatologist; 4. Documentation of history of failure to one traditional disease‑modifying antirheumatic drug (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine), unless contraindicated (document drug, date and duration of trial); 5. Documentation of history of failure to two of the following medications unless contraindicated or clinically significant adverse effects are experienced: Cimzia, Enbrel, Rinvoq, Simlandi, Xeljanz (polyarticular JIA only) (document drugs, dates, duration of trials); 6. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

Initial Authorization — Rheumatoid Arthritis

Covered when ALL of the following are met for rheumatoid arthritis (initial):

RA Initial Criteria: 1. Documented diagnosis of moderately to severely active rheumatoid arthritis; 2. Patient is at least 18 years of age or older; 3. Prescribed by a rheumatologist; 4. Documentation of history of failure to one traditional disease‑modifying antirheumatic drug (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine), unless contraindicated (document drug, date and duration of trial); 5. Documentation of history of failure to two of the following medications unless contraindicated or clinically significant adverse effects are experienced: Cimzia, Enbrel, Rinvoq, Simlandi, Simponi, Xeljanz (document drugs, dates, duration of trials); 6. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

Initial Authorization — Systemic Sclerosis-Associated ILD

Covered when ALL of the following are met for systemic sclerosis-associated interstitial lung disease (initial):

SSc-ILD Initial Criteria: 1. Documented diagnosis of systemic sclerosis‑associated interstitial lung disease; 2. Prescribed by an appropriate specialty (rheumatologist or pulmonologist as indicated); 3. Documentation of history of failure to two of the following medications unless contraindicated or clinically significant adverse effects are experienced: azathioprine, cyclophosphamide, mycophenolate mofetil (document drugs, dates, duration of trials); 4. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

Reauthorization Criteria

Reauthorization (for applicable indications):

Reauthorization Criteria: 1. Documentation the patient/member has been established on the requested medication for at least 12 months; 2. Diagnosis consistent with the approved indication; 3. Prescribed by the appropriate specialty; 4. Documentation of clinically significant improvement or stabilization in clinical signs and symptoms as determined by the prescriber; 5. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.12 months

Approval requires at least 12 months on therapy prior to reauthorization.

Program-level Coverage Requirements

Program-level coverage criteria and operational requirements

Authorization duration and reauthorization: Approval for biologic and targeted immunomodulator therapies is limited to 12 months and requires annual reauthorization.12 months

Effective 1/1/26; annual reauthorization criteria added.

Duplication prevention: Coverage criteria include provisions to prevent duplicative targeted immunomodulator therapy (concurrent overlapping targeted agents).N/A

Added to prevent duplicative therapy.

Preferred product and prerequisites: Formulary preferences and biologic prerequisites updated (e.g., Simlandi preferred adalimumab; Rinvoq, Xeljanz, and Cimzia added to pJIA prerequisites as of noted effective dates).N/A

Samples, free goods, or similar offerings of the requested medication do not qualify as evidence of an established clinical response and will not be considered for prior authorization. Providers should document clinically appropriate, verifiable trials of therapy in the medical record rather than relying on sample or promotional supplies when requesting coverage.

Documentation that a patient has a needle phobia or that administration is inconvenient does not qualify as a medically acceptable contraindication to injectable products. This limitation was specifically removed from prior language effective 1/1/2024 and remains part of the policy's exclusion criteria.

Documentation that a member is a social drinker does not qualify as a medically acceptable contraindication or clinical inappropriateness to methotrexate therapy. Social alcohol use alone should not be used as the rationale to deny methotrexate or to justify alternative therapies without additional clinical justification.

The Pharmacy Medical Necessity Guidelines are intended to guide coverage decisions but do not guarantee payment. Claims adjudication remains subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization requirements, utilization management rules, adherence to plan policies and procedures, and claims editing logic; for self‑insured plans, the benefit document governs in case of discrepancy.

Billing and Coding

Codesmixed

No codes listed

Codes listedmixed

No codes listed

Provider Actions and Requirements

Prior Authorization

Prior authorization required for Actemra SC

Prior authorization is required for Actemra (tocilizumab) subcutaneous for Harvard Pilgrim Health Care and Tufts Health Plan commercial products. Fax submission contact is provided in the policy materials for these commercial products.

Prior Authorization

Authorization required; approval limited to 12 months

Prior authorization is required for biologic and targeted immunomodulator therapies per the Pharmacy Medical Necessity Guidelines. Approvals are limited to 12 months and require annual reauthorization.

Step Therapy

Step therapy: required prior medication trials

Documented failure of specified traditional DMARD(s) is required and, for many indications, documented failure of two listed biologic or targeted agents is required prior to approval.

Background and Drug Information

Tocilizumab (Actemra) is an interleukin‑6 (IL‑6) receptor antagonist used in multiple rheumatologic and related conditions including giant cell arteritis, juvenile idiopathic arthritis, rheumatoid arthritis, and systemic sclerosis‑associated interstitial lung disease. The drug is available as a subcutaneous formulation and is prescribed by appropriate specialists (for example, rheumatologists or neurologists depending on indication).

These guidelines align authorization with FDA‑approved indications and standard specialty prescriber expectations and require documentation of prior therapy trials, appropriate prescriber specialty, and absence of concurrent biologic or targeted synthetic oral small‑molecule therapy when applicable. Authorization durations and program-level requirements (such as the 12‑month approval interval and annual reauthorization) are also specified within the policy framework.

Definitions

inv-22: Actemra (tocilizumab) subcutaneous — Key drug definition

Drug classInterleukin-6 (IL-6) receptor antagonist

Generic nametocilizumab (subcutaneous) — Actemra

FDA‑approved indications (selected)Giant cell arteritis; Juvenile idiopathic arthritis; Rheumatoid arthritis; Systemic sclerosis‑associated interstitial lung disease

Typical prescribing specialtiesRheumatology; Neurology (for GCA); Pulmonology (for SSc‑ILD as indicated)

Policy relevanceAuthorization criteria align with the FDA‑approved indications listed for Actemra subcutaneous

inv-23: Pharmacy Medical Necessity Guidelines — Definition and purpose of the guidelines used for determinations

Policy Revision History

2025-12-09preferred_product_changeLatest

Replaced Humira with Simlandi as the preferred adalimumab product (effective 2026-03-01).

2025-10-14policy_revision

Approvals limited to 12 months and annual reauthorization criteria added; provider requirements updated to remove 'with in consultation with the specialist'; added criteria to prevent duplicative targeted immunomodulator therapy and updated diagnosis/initial authorization language (effective 2026-01-01).

2024-06-11

Policy Summary

Payerharvard pilgrim health care

PolicyActemra (tocilizumab) subcutaneous — Prior Authorization Coverage Criteria

Policy CodePolicy N/A

Change TypeMaterial coverage and operational updates (approval limits, reauthorization, preferred product change)

Effective DateMar 1, 2026

Last ReviewOct 14, 2025

Next Review DateN/A

SourceLink

On This Page

Product preference change effective 3/1/26; pJIA prerequisite updates effective 7/1/24 and 7/1/25.

Administrative eligibility: Coverage is contingent on member eligibility, benefit terms, and adherence to plan policies; for self‑insured plans, the benefit document governs in case of discrepancy.N/A

Standard administrative conditions.

pJIA: failure of one traditional DMARD and two of the listed biologic/targeted agents (cimzia, enbrel, rinvoq, simlandi, Xeljanz for polyarticular JIA).
RA: failure of one traditional DMARD and two of the listed agents (cimzia, enbrel, rinvoq, simlandi, simponi, Xeljanz).
SSc‑ILD: failure of two agents among azathioprine, cyclophosphamide, mycophenolate mofetil.

Billing Rule

Preferred agents and duplicate therapy prevention

Formulary preferences and biologic prerequisites have been updated; Simlandi is now the preferred adalimumab product and criteria include provisions to prevent duplicative targeted immunomodulator therapy.

Preferred product change: Simlandi replaced Humira as preferred adalimumab (effective 3/1/26).
Policy now includes criteria to prevent concurrent overlapping targeted immunomodulator therapy.

Documentation Required

Required documentation to support authorization

Providers must document the patient’s diagnosis, age, prescriber specialty, prior medication trials with specific drug names, dates, and duration of trials, and that the patient is not receiving the requested medication in combination with another biologic or targeted synthetic oral small molecule.

For corticosteroid requirement in giant cell arteritis: document drug, date and duration of systemic corticosteroid trial (or contraindication).
For traditional DMARD and biologic trials: document drug names, dates, and duration of each trial.

Documentation Required

Documentation and annual reauthorization requirements

Providers must supply clinical justification consistent with the Pharmacy Medical Necessity Guidelines; the plan may require documentation at authorization and annual reauthorization to support continued coverage.

Reauthorization requires documentation the member has been on the medication for at least 12 months and evidence of clinically significant improvement or stabilization.

Denial Risk

Denial risk for missing prior or concomitant therapy documentation

Failure to document required prior therapy trials or to show the absence of concomitant use with another biologic or targeted small molecule may result in denial of the request.

Giant cell arteritis: lack of documented systemic corticosteroid trial (drug/date/duration) when required may trigger denial.
JIA/RA/SSc‑ILD: missing documentation of required DMARDs or biologic/targeted agent trials may trigger denial.
Concurrent use documented with another biologic or targeted synthetic oral small molecule is not allowed and may lead to denial.

Denial Risk

Administrative and eligibility triggers for denial

Coverage determinations are made case‑by‑case and payment is subject to member eligibility, benefit terms, coordination of benefits, referral/authorization rules, and utilization management; discrepancies for self‑insured plans are governed by the benefit document.

Claims payment is also subject to claims editing logic and adherence to plan policies and procedures.

PurposePharmacy Medical Necessity Guidelines are developed to determine coverage for plan benefits by providing concise clinical coverage criteria for selected therapeutic classes or drugs.

Basis for recommendationsCurrent literature review, consultation with practicing physician experts, FDA and government agency policies, and national accreditation standards.

Use and limitationsGuidelines inform coverage decisions on a case‑by‑case basis but do not guarantee payment; claims adjudication remains subject to member eligibility, benefits, and plan procedures.

MaintenanceGuidelines are revised and updated annually or more frequently when new evidence requires revisions.

Applicability to self‑insured plansIf a discrepancy exists between a guideline and a self‑insured member's benefit document, the benefit document governs.

Updated biologic prerequisites for polyarticular juvenile idiopathic arthritis to include Rinvoq and Xeljanz (effective 2024-07-01).

2023-12-12limitations_removed

Removed limitation language stating needle phobia (and inconvenience to phototherapy for plaque psoriasis) qualifies as a contraindication (effective 2024-01-01).

2022-09-13committee_review

Reviewed by the Pharmacy & Therapeutics Committee; prior e-vote in Sept 2022 added Enbrel as a preferred agent effective 2023-01-01.